Mr. LePore has more than 30-years of extensive experience in all areas of executive management including executive development, strategic planning, mergers and acquisition, business development, investor relations and corporate governance. Most notably, Mr. LePore served as Chairman, CEO and President of Par Pharmaceuticals, Inc. (NYSE: PRX) from September 2006 through November 2012. Par Pharmaceuticals, a fully integrated healthcare company, was a leader in the development, licensing, manufacturing and distribution of generic and branded drugs. During his tenure, Mr. LePore oversaw the management of over 2,000 employees with facilities in New York, California and Chennai India. He also oversaw the growth of its brand division, Strativa, its sales force and the acquisition of several products.
Through Mr. LePore’s leadership, Par increased its value and market presence culminating in its sale to Texas Pacific Group (TPG), in a go private transaction, for approximately $2 billion. Mr. LePore transitioned to Chairman of the new company beginning in November 2012 and directed its eventual sale to Endo (NASDAQ: ENDP) for over $8 billion in 2015. He began his career with Hoffmann La Roche and then founded Boron LePore and Associates, a medical communications company, which he took public in 1997 and was eventually sold to Cardinal Health in 2002.